PriceTargets.com logo

ProQR Therapeutics - PRQR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.60
  • Forecasted Upside: 188.97%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$2.63 As of 12/20/2024 06:16 PM ET
▲ +0.04 (1.54%)

This chart shows the closing price for PRQR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ProQR Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRQR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRQR

Analyst Price Target is $7.60
▲ +188.97% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $7.60, with a high forecast of $14.00 and a low forecast of $2.00. The average price target represents a 188.97% upside from the last price of $2.63.

This chart shows the closing price for PRQR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in ProQR Therapeutics. This rating has held steady since October 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$8.00 ➝ $8.00
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
12/12/2024Chardan CapitalReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
11/8/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $10.00
10/29/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$6.00 ➝ $14.00
5/10/2024Chardan CapitalReiterated RatingBuy ➝ Buy$2.50 ➝ $2.50
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
4/18/2024CitigroupBoost TargetBuy ➝ Buy$1.80 ➝ $2.00
3/14/2024Chardan CapitalBoost TargetBuy ➝ Buy$2.00 ➝ $2.50
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
11/8/2023Raymond JamesLower TargetOutperform ➝ Outperform$5.00 ➝ $4.00
11/8/2023Chardan CapitalUpgradeNeutral ➝ Buy$2.00
9/18/2023CitigroupLower TargetBuy ➝ Buy$2.10 ➝ $1.80
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00
8/4/2023Chardan CapitalReiterated RatingNeutral ➝ Neutral$2.00
5/17/2023Cantor FitzgeraldLower Target$5.00 ➝ $4.50
4/7/2023CitigroupLower Target$3.00 ➝ $2.25
3/30/2023HC WainwrightBoost TargetBuy$1.50 ➝ $5.00
3/30/2023JMP SecuritiesUpgradeMarket Perform ➝ Outperform$1.50 ➝ $5.00
12/23/2022Raymond JamesBoost TargetOutperform$2.00 ➝ $5.00
12/22/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight$5.00
8/15/2022Cantor FitzgeraldDowngradeOverweight ➝ Neutral
8/12/2022Raymond JamesUpgradeMarket Perform ➝ Outperform$2.00
8/12/2022Chardan CapitalDowngradeBuy ➝ Neutral
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
5/9/2022HC WainwrightLower Target$4.00 ➝ $2.00
4/19/2022Cantor FitzgeraldLower Target$6.00 ➝ $3.50
4/14/2022JMP SecuritiesLower TargetMarket Outperform$8.00 ➝ $5.00
4/14/2022Chardan CapitalLower TargetBuy$8.00 ➝ $2.50
2/14/2022Chardan CapitalLower TargetBuy$18.00 ➝ $8.00
2/14/2022JMP SecuritiesLower TargetMarket Outperform$29.00 ➝ $8.00
2/14/2022HC WainwrightLower TargetBuy$20.00 ➝ $4.00
2/13/2022CitigroupDowngradeBuy ➝ Hold
2/11/2022Raymond JamesDowngradeStrong-Buy ➝ Market Perform
2/11/2022Stifel NicolausDowngradeBuy ➝ Hold$20.00 ➝ $3.00
2/1/2022Raymond JamesInitiated CoverageStrong-Buy$19.00
11/7/2021Evercore ISIReiterated RatingBuy$17.00
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
9/30/2021JMP SecuritiesReiterated RatingBuy$31.00
9/12/2021Evercore ISIReiterated RatingBuy
9/10/2021Chardan CapitalReiterated RatingBuy$18.00
9/9/2021HC WainwrightReiterated RatingBuy$20.00
9/9/2021JMP SecuritiesReiterated RatingBuy$31.00
8/9/2021Chardan CapitalLower TargetBuy$20.00 ➝ $18.00
5/3/2021Stifel NicolausInitiated CoverageBuy$20.00
3/25/2021CitigroupBoost Target$33.00 ➝ $44.00
3/24/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$22.00 ➝ $33.00
3/24/2021JMP SecuritiesBoost TargetOutperform$19.00 ➝ $35.00
10/9/2020Cantor FitzgeraldReiterated RatingOverweight
10/1/2020Cantor FitzgeraldReiterated RatingOverweight
8/11/2020Chardan CapitalLower TargetBuy$25.00 ➝ $20.00
7/21/2020Chardan CapitalReiterated RatingBuy$25.00
7/21/2020HC WainwrightReiterated RatingBuy$20.00
6/23/2020Chardan CapitalReiterated RatingBuy$25.00
5/11/2020HC WainwrightReiterated RatingBuy
4/1/2020Chardan CapitalReiterated RatingBuy$25.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ProQR Therapeutics logo
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Read More

Today's Range

Now: $2.63
Low: $2.47
High: $2.70

50 Day Range

MA: $3.48
Low: $1.81
High: $4.49

52 Week Range

Now: $2.63
Low: $1.61
High: $4.62

Volume

718,766 shs

Average Volume

533,940 shs

Market Capitalization

$214.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of ProQR Therapeutics?

The following sell-side analysts have issued research reports on ProQR Therapeutics in the last year: Chardan Capital, Citigroup Inc., HC Wainwright, JMP Securities, Raymond James, and StockNews.com.
View the latest analyst ratings for PRQR.

What is the current price target for ProQR Therapeutics?

0 Wall Street analysts have set twelve-month price targets for ProQR Therapeutics in the last year. Their average twelve-month price target is $7.60, suggesting a possible upside of 189.0%. Raymond James has the highest price target set, predicting PRQR will reach $14.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $2.00 for ProQR Therapeutics in the next year.
View the latest price targets for PRQR.

What is the current consensus analyst rating for ProQR Therapeutics?

ProQR Therapeutics currently has 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRQR will outperform the market and that investors should add to their positions of ProQR Therapeutics.
View the latest ratings for PRQR.

What other companies compete with ProQR Therapeutics?

Other companies that are similar to ProQR Therapeutics include Anavex Life Sciences, Immunome, Kura Oncology, Keros Therapeutics and Tyra Biosciences. Learn More about companies similar to ProQR Therapeutics.

How do I contact ProQR Therapeutics' investor relations team?

ProQR Therapeutics' physical mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company's listed phone number is (188) 166-7000 and its investor relations email address is [email protected]. The official website for ProQR Therapeutics is www.proqr.com. Learn More about contacing ProQR Therapeutics investor relations.